Short Term Portfolio

IMMX

Added at slight dip, more detail to be added tomorrow

OSTX
- 2nd Entry
- FDA Type C meeting scheduled for December.
- Pritority Review Voucher play might be still in game
- Cash runway is concern

CADL
- Great cash runway (over 3 years)
- Promising MoA and oncology efficacy
- Conference presentations on 7th November

XLO
- Exceptional potential, big interests from big pharmas
- Funding is sufficient into 2027, however dilution is big concern
- Clinical trials early stage, 1/2, and preclinical
- Validation of efficacy will be essential
- Few near term catalysts on 7th November with additional data expected
- Long term investment potential

ABEO
- Commercialisation ready
- Undervalued for the potential of its approved pipeline
- May consider moving to long term portfolio

IMRN (Exit on 31/Oct due to delay in phase 2 top line results, apparently due to the shut down)
- Earnings mid October
- Phase 2 results for their main product Travelan is anticipated in October with EOP2 meeting with FDA planned after the read out
- Cash is concern, and I plan to exit with a news.

PEPG (Exit on 27/Oct at $5.40 pre-market)
- Promising DM1 data
- 3-6 months hold for now, may move to long term portfolio later
- Exited with a small gain affected by Avidity's acquisition

OMER (Exit on 20/Oct at $8.05 at loss)
- Added with NVO's licensing news on 15th of October,2025
- Phase 3 asset out-licensing with good upfront fee, milestones and tiered royalties up to $2.1B.
- PDUFA also coming at the end of the year
- May add little more if the price falls below $8, may consider holding through next year
- Exited due to loss of momentum

DYN (Exit on 20/Oct at $17.06)
- Phase 1/2 for DMD is expected before the end of the year, anticipation run expected
- Cash runway good into 2027 with recent dilution
- Good candidate for both short & long term, RNA is challenging DM1 pipeline with more advanced regulatory progress, but DYN has edge with multiple pipelines and can be considered undervalued at the moment.
- Target hit

SLS (Exit on 17/Oct at $2.38 after market spike)
- Presentation for progress on highly anticipated Phase 3 REGAL is planned on 29th October
- Phase 3 data to be expected before the EOY.

KYTX (Exit on 8/Oct at $7.6)
- October 29 Catalyst for KYV-101 on Myasthenia gravis Phase 2 Interim Data
- Another Phase 1 additional data to be expected in H2 2025
- Phase 2 for Stiff-person syndrome is expected in first half of 2026, if the result are good BLA is planned for late 2026
- Cash runway good into Q1 2027
- Great potential for long term as well

OSTX (Exit on 10/Oct at $2.38 with a spike)
- 10th of October and 13th of October, data release and presentation
- BLA planned
- Cash is concern, short-term swing idea.

MLTX (I exited between $7.40~$8.30 Final Exit on 7/Oct)
- Oversold due to recent near miss Phase 3 trial
- Market cap near cash level
- Strong potential for rebound with upcoming catalysts
- Candidate for both short & long term